The short version
- A 2023 meta-analysis of 26 randomised trials in 1,691 women found those taking inositol were 1.79 times as likely to have a regular menstrual cycle as those on placebo (95% CI 1.13 to 2.85).
- In the same analysis, inositol showed non-inferiority to metformin on cycle normalisation, and produced greater reductions than placebo in BMI, total and free testosterone, androstenedione and glucose.
- A 2026 umbrella review graded 85 evidence items from 13 meta-analyses and found no high-quality evidence: 18.9% were moderate, 40% low and 41.1% very low quality.
- That umbrella review found myo-inositol, alone or with folic acid, was superior for metabolic and reproductive outcomes, and advised caution with D-chiro-inositol monotherapy.
- A 2018 Cochrane review of 13 trials in 1,472 subfertile women with PCOS concluded it is uncertain whether myo-inositol improves live birth or clinical pregnancy rates, on very low-quality evidence.
Most supplements aimed at women with polycystic ovary syndrome have a mechanism and a testimonial. Inositol has twenty-six randomised controlled trials. That alone puts it in a different tier, and it is why this article exists — not to sell you anything, because we do not make it, but because the trial record deserves reading properly rather than in the summarised form it usually arrives in.
The best-organised positive result
In 2023, a Hungarian group published a systematic review and meta-analysis in Reproductive Biology and Endocrinology covering 26 randomised trials and 1,691 women — 806 taking an inositol, 311 on placebo, 509 on metformin. Their primary outcome was cycle normalisation.
Women on inositol were 1.79 times as likely to have a regular menstrual cycle as women on placebo, with a confidence interval of 1.13 to 2.85. Against metformin, inositol showed non-inferiority on that outcome. Compared with placebo, it also produced greater reductions in BMI (-0.45), free testosterone (-0.41), total testosterone (-20.39), androstenedione (-0.69) and glucose (-3.14), and a rise in sex-hormone-binding globulin of 32.06.
Non-inferior to the standard insulin sensitiser, on the outcome that matters most to a lot of women, without metformin's gastrointestinal burden. If you have read that inositol is the one supplement in this space with real backing, this is the paper behind the claim, and it is a legitimate one.
Now the part that comes with it
In 2026 a Chinese group ran an umbrella review — a review of the meta-analyses — in Frontiers in Endocrinology. Thirteen meta-analyses. Eighty-five separate evidence items graded with GRADE.
Not one was rated high quality. 18.9% were moderate, 40% low, and 41.1% very low. On AMSTAR-2, only 23.1% of the included meta-analyses were themselves rated high quality.
The pooled effects were still there — HOMA-IR down 1.14, fasting insulin down 23.40 pmol/L, ovulation rate risk ratio 2.75, live births 2.29 — and the moderate-quality findings clustered around testosterone, SHBG, HOMA-IR and pregnancy and ovulation rates. But against metformin, most differences were not significant. And the reviewers separated the forms: myo-inositol, alone or with folic acid, was superior for metabolic and reproductive outcomes, while they advised caution with D-chiro-inositol on its own and found that combination products did not consistently beat single forms.
That last detail is the practical one. The 40:1 blends dominate the shelf, and the umbrella review does not find them consistently better than plain myo-inositol.
The Cochrane review, which is the coldest read
Cochrane looked at a narrower question in 2018: inositol for subfertile women with PCOS, 13 trials and 1,472 women, mostly as pre-treatment before IVF. Their verdict on live birth: uncertain, odds ratio 2.42 with a confidence interval running from 0.75 to 7.83 across two trials and 84 women. On clinical pregnancy: uncertain again. Overall quality, low to very low.
They also did something we admire. An apparent reduction in miscarriage disappeared when they removed a single trial with an unusually high control-group rate. That is what honest sensitivity analysis looks like, and it is exactly the check that does not happen before a claim reaches a product page.
So three reviews, three tones — positive, cautiously positive, and unconvinced — because they asked different questions of a literature that is genuinely mixed. The reconciliation is straightforward: inositol looks better on cycles, androgens and insulin markers than it does on babies, and none of it rests on high-quality evidence yet.
What we would not say
We would not say inositol treats PCOS. PCOS is a diagnosis, it carries implications for fertility, cardiometabolic risk and long-term health, and it is managed by a clinician who knows your bloodwork. A supplement can support normal insulin sensitivity and normal menstrual regularity; it does not replace a care plan, and the papers above were all run alongside medical management rather than instead of it.
We would also not tell you this is a general-purpose insulin supplement. Almost everything measured above was measured in women with PCOS. That is a specific physiology, and the results do not transfer to someone with a normal panel any more than the chromium results transfer out of the diabetic groups they came from.
What we'd actually tell you
If you have PCOS and you are considering inositol, take the studies to your appointment rather than the marketing. Ask about myo-inositol specifically, at the doses the trials used, for at least three months, and ask what you will measure at the end — cycle length, testosterone, HOMA-IR. Something checkable.
And judge it on that, not on the scale. If you are hoping for weight change, be clear that BMI moved by less than half a point in the pooled analysis, which is roughly what everything else on the weight-loss shelf produces. This ingredient's case is about cycles and androgens. That is a better case than most, and it is the one worth holding it to.
Good questions
Does inositol actually work for PCOS?
It has the strongest trial record of anything sold for PCOS, which is a lower bar than it sounds. Twenty-six randomised trials show better cycle regularity than placebo and results comparable to metformin, but an umbrella review of the whole field found no high-quality evidence for any single outcome. Real signal, immature evidence base, and a diagnosis that still needs a clinician.
Should I take myo-inositol or a 40:1 blend?
The 2026 umbrella review found myo-inositol on its own, or with folic acid, was superior for metabolic and reproductive outcomes, and that combination products did not consistently outperform single forms. It also advised caution with D-chiro-inositol used alone. The 40:1 ratio dominates the shelf on the strength of a mechanism story rather than a consistent trial advantage.
Can inositol replace metformin?
That is not your decision or ours to make. Pooled trials show comparable results on cycle normalisation and mostly non-significant differences on other measures, which is interesting but is not the same as an equivalence study designed for the purpose. Metformin is a prescription with decades of data behind it, and stopping one is a conversation with the doctor who started it.
Will inositol help me get pregnant?
Cochrane's answer is that we do not know. Across 13 trials in 1,472 subfertile women with PCOS, the effect on live birth was uncertain, with a confidence interval spanning from no benefit to a large one, on very low-quality evidence. Fertility treatment decisions deserve better data than that, and your clinic will have it.
How long before inositol does anything?
The trials generally ran for three months or longer, so judge it on that timescale rather than weeks. Decide in advance what you will measure — cycle length, a testosterone panel, HOMA-IR — and check it at the end. Cycle regularity is the outcome with the most consistent support, so it is the fairest thing to hold it to.
Will inositol help me lose weight?
Not meaningfully. The pooled BMI difference against placebo was 0.45 points, which is the same order of magnitude as the rest of the weight-loss category and not something you would notice. If weight is your goal, this ingredient's evidence is not about that, and buying it for that reason sets you up to be disappointed by a product that is doing something else.
Sources
- Greff D, Juhász AE, Váncsa S, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol, 2023. View study
- Duan M, Yang M, Li C, Wu X, Yin X, Zhu H. Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials. Front Endocrinol (Lausanne), 2026. View study
- Showell MG, Mackenzie-Proctor R, Jordan V, Hodgson R, Farquhar C. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev, 2018. View study
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
